AquaBounty Technologies, Inc. (NasdaqCM: AQB)
Health Care · Biotechnology · US
$1.33
+1.53% today · +75.0% 1Y
AquaBounty Technologies, Inc. (NasdaqCM: AQB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.85M and employs 3 people.
Over the last twelve months the share price has gained 75.0%, trading between 0.71 and 2.95.
Tweenvest scores AquaBounty Technologies, Inc. across four factors: quality 29/100. Its strongest factor is quality.
AQB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.85M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.20
- Dividend yield
- —
- Beta (5Y)
- 1.40
- 52-week high
- $2.95
- 52-week low
- $0.71
- Avg volume (3M)
- —
- Shares outstanding
- 5.15M
- Employees
- 3
- Next earnings
- —
About AquaBounty Technologies, Inc.
AquaBounty Technologies, Inc. is a biotechnology firm dedicated to boosting productivity within the commercial fish farming sector across the United States and Canada. The company's research initiatives delve into genetics, genomics, fish health, and nutrition. Its flagship offering is AquAdvantage Salmon, a genetically engineered Atlantic salmon intended for human consumption. Beyond this, AquaBounty also supplies conventional Atlantic salmon, along with salmon eggs, juvenile fish (fry), and various byproducts. Established in 1991, the firm maintains its headquarters in Maynard, Massachusetts. It operated under the name Aqua Bounty Farms, Inc. until its rebranding in June 2004.
- ISIN
- US03842K3095
- Founded
- 1991
- Listed since
- Jan 11, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.